AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Vericel to Present at Multiple Upcoming Conferences

September 21, 2018

CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences:

-- Nick Colangelo, president and CEO, will present at the Ladenburg 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 11:30 AM EDT http://wsw.com/webcast/ladenburg4/vcel/ -- Nick Colangelo, president and CEO, will present at the Cantor Global Healthcare Conference in New York, NY on Wednesday, October 3, 2018 at 1:40 PM EDT http://wsw.com/webcast/cantor7/vcel/ -- Dan Orlando, Chief Operating Officer, will present at the Cell & Gene Meeting on the Mesa in La Jolla, CA on, Thursday, October 4, 2018 at 5:15 PM PDT http://www.meetingonthemesa.com/webcast

About Vericel CorporationVericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company’s website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.

Global Media Contacts:David SchullRusso Partners LLC+1 212-845-4271 (office)+1 858-717-2310 (mobile)David.schull@russopartnersllc.com

Karen ChaseRusso Partners LLC+1 646-942-5627 (office)+1 917-547-0434 (mobile)Karen.chase@russopartnersllc.com

Investor Contacts:Chad RubinSolebury Troutcrubin@troutgroup.com+1 (646) 378-2947

Lee SternSolebury Troutlstern@troutgroup.com+1 (646) 378-2922